12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bupropion regulatory update

Germany's IQWiG said in a cost-benefit assessment that the cost of each of 4 antidepressants - bupropion, duloxetine, mirtazapine and venlafaxine - is above the threshold determined by IQWiG to be cost-effective. However, IQWiG conceded that limited data regarding cost and certain endpoints, including quality of life, contributed to uncertainty in the assessment.

IQWiG said that Germany's Federal Joint Committee (G-BA) charged IQWiG with carrying out the assessments in December 2009, before Germany's new...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >